Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study

Yıl: 2022 Cilt: 3 Sayı: 2 Sayfa Aralığı: 99 - 107 Metin Dili: İngilizce DOI: 10.4274/hamidiyemedj.galenos.2022.07078 İndeks Tarihi: 19-08-2022

Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study

Öz:
Background: To investigate the effects of tannic acid (TA) use on ovarian folliculogenesis, p53 expression, and serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone (T) levels in rats with polycystic ovary syndrome (PCOS) model. Materials and Methods: A total of 18 Wistar female rats were used and divided into 3 experimental groups. Group 1 (G1, control), group 2 (G2, PCOS), group 3 (G3, PCOS+TA). Rats were induced with letrozole for 21 days to form a PCOS model. After 21 days, TA (40 mg/kg) was given by gavage for 10 days and the rats were sacrificed on the 10th day. PCOS formation was evaluated by daily estrous cycle follow-up. Hematoxylin & eosin and p53 immunohistochemical staining was performed on ovaries. Serum FSH, LH, and T levels were determined by ELISA. Data were analyzed with the One-Way ANOVA test and Kruskal-Wallis H test. P<0.05 was considered statistically significant. Results: The number of cystic follicles was significantly increased in the PCOS group compared to the TA treatment group (p<0.05). The number of primary follicles was significantly increased in the TA treatment group (p<0.001). No significant change was observed in the number of primordial, secondary, and Graaf follicles between the experimental groups. A significant increase in LH and T was observed in the PCOS group (p<0.05). The increase in LH has significantly decreased TA administered rats (p<0.05). Although it was not significant, serum FSH level was increased in the PCOS+TA group. No immunoreactivity was detected in p53 staining in experimental groups. Conclusion: TA can decrease cystic follicle formation and increase primary follicle formation in PCOS. Also, it can regulate the hormonal expression of serum LH, FSH, and T in PCOS-modeled rats.
Anahtar Kelime:

Sıçanlarda Letrozol ile Oluşturulan Polikistik Over Sendromu (PKOS) Modelinde Tannik Asitin Terapötik Potansiyeli: Histolojik ve Biyokimyasal Çalışma

Öz:
Amaç: Polikistik over sendromu (PKOS) modeli oluşturulmuş sıçanlarda tannik asit (TA) kullanımının ovaryan folikülojenez, p53 ekspresyonu ve serum lüteinizan hormon (LH), folikül uyarıcı hormon (FSH) ve testosteron (T) seviyeleri üzerindeki etkilerini araştırmaktır. Gereç ve Yöntemler: Toplam 18 Wistar dişi sıçan kullanıldı ve 3 deney grubuna ayrıldı: Grup 1 (G1, kontrol), grup 2 (G2, PKOS), grup 3 (G3, PKOS+TA). Sıçanlara, PCOS modeli oluşturmak için 21 gün boyunca letrozol verildi. Yirmi bir gün sonra TA (40 mg/kg) 10 gün boyunca gavaj yoluyla verildi ve sıçanlar 10. günde sakrifiye edildi. PKOS oluşumu günlük östrus döngüsü takibi ile değerlendirildi. Over dokusunda hematoksilen & eosin ve p53 immünohistokimyasal boyamaları yapıldı. Serum FSH, LH ve T seviyeleri ELISA ile belirlendi. Veriler One-Way ANOVA testi ve Kruskal-Wallis H testi ile analiz edildi. P<0,05 istatistiksel olarak anlamlı kabul edildi. Bulgular: PKOS grubunda kistik folikül sayısı TA tedavi grubuna göre anlamlı olarak arttı (p<0,05). TA tedavi grubunda primer folikül sayısı anlamlı olarak arttı (p<0,001). Deney grupları arasında primordial, sekonder ve Graaf foliküllerinin sayısında önemli bir değişiklik gözlenmedi. PKOS grubunda LH ve T’de anlamlı bir artış gözlendi (p<0,05). TA uygulanan sıçanlarda LH seviyesinde önemli ölçüde azalma gözlendi (p<0,05). PKOS+TA grubunda anlamlı olmasa da serum FSH düzeyi arttı. Deney gruplarında p53 boyamasında immünoreaktivite saptanmadı. Sonuç: TA, PKOS’de kistik folikül oluşumunu azaltabilir ve primer folikül oluşumunu artırabilir. Ayrıca TA, PKOS modelli sıçanlarda serum LH, FSH ve T’nin hormonal ekspresyonunu düzenleyebilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-861. [Crossref]
  • 2. Speroff L. Fritz MA. Eds. Clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkins; 2005. [Crossref]
  • 3. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin- insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302. [Crossref]
  • 4. Franks S, Roberts R, Hardy K. Gonadotrophin regimens and oocyte quality in women with polycystic ovaries. Reprod BioMed Online. 2003;6:181- 184. [Crossref]
  • 5. Wood JR, Dumesic DA, Abbott DH, Strauss JF 3rd. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab. 2007;92:705-713. [Crossref]
  • 6. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009;69:1821-1827. [Crossref]
  • 7. Yaba A, Bianchi V, Borini A, Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod Sci. 2008;15:128-138. [Crossref]
  • 8. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14:367-378. [Crossref]
  • 9. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C, et al. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod. 2006;12:475-481. [Crossref]
  • 10. Sander VA, Facorro GB, Piehl L, Rubín de Celis E, Motta AB. Effect of DHEA and metformin on corpus luteum in mice. Reproduction. 2009;138:571- 579. [Crossref]
  • 11. Braillon A. Polycystic ovary syndrome. N Engl J Med. 2005;352:2756-2757. [Crossref]
  • 12. Johansson J, Stener-Victorin E. Polycystic ovary syndrome: Effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med. 2013;2013:762615. [Crossref]
  • 13. Naseri L, Khazaei MR, Khazaei M. Synergic effect of bee pollen and metformin on proliferation and apoptosis of granulosa cells: Rat model of polycystic ovary syndrome. J Food Biochem. 2022;46:e13635.
  • 14. Aksoy S, Armutcu F, Yiğitoglu MR. Using of caffeic acid phenetil ester (CAPE) the active substance of propolis in some neurologic disease and emergency. Spatula DD. 2011;1:37-42. [Crossref]
  • 15. D’Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita. 2007;43:348-361. [Crossref]
  • 16. Zhao ZJ, Wang DH. Effects of diet quality on energy budgets and thermogenesis in Brandt’s voles. Comp Biochem Physiol A Mol Integr Physiol. 2007;148:168-177. [Crossref]
  • 17. Min BR, Fernandez JM, Barry TN, McNabb WC, Kemp PD. The effect of condensed tannins in Lotus corniculatus upon reproductive efficiency and wool production in ewes during autumn. Anim Feed Sci Technol. 2001;92:185-202. [Crossref]
  • 18. Sen HM, Ozkan A, Guven M, Akman T, Aras AB, Sehitoglu I, et al. Effects of Tannic Acid on the Ischemic Brain Tissue of Rats. Inflammation. 2015;38:1624-1630. [Crossref]
  • 19. Ahmad T. Reviewing the tannic acid mediated synthesis of metal nanoparticles. Journal of Nanotechnology. 2014;11:18-39. [Crossref]
  • 20. Sahiner N, Sengel SB. Tannic acid decorated poly (methacrylic acid) micro and nanoparticles with controllable tannic acid release and antioxidant properties. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2016;508:30-38. [Crossref]
  • 21. Sahiner N, Sagbas S, Aktas N, Silan C. Inherently antioxidant and antimicrobial tannic acid release from poly (tannic acid) nanoparticles with controllable degradability. Colloids Surf B Biointerfaces. 2016;142:334- 343. [Crossref]
  • 22. Dai X, Zou ZZ, Zhang TT, Jiang W, Wei WH, Yang SM. The effect of tannic acid on the gonad hormones in plateau pikas (Ochotona curzoniae) and root voles (Microtus oeconomus). Acta Theriol Sinica. 2011;31:278-283. [Crossref]
  • 23. Spinaci M, Volpe S, De Ambrogi M, Tamanini C, Galeati G. Effects of epigallocatechin-3-gallate (EGCG)-on in vitro maturation and fertilization of porcine oocytes. Theriogenology. 2008;69:877-885. [Crossref]
  • 24. Ekambaram G, Sampath Kumar SK, Joseph LD. Comparative Study on the Estimation of Estrous Cycle in Mice by Visual and Vaginal Lavage Method. J Clin Diagn Res. 2017;11:AC05-AC07. [Crossref]
  • 25. Souza AZ, Fonseca AM, Izzo VM, Clauzet RM, Salvatore CA. Ovarian histology and function after total abdominal hysterectomy. Obstet Gynecol. 1986;68:847-849. [Crossref]
  • 26. Wang F, Wang S, Zhang Z, Lin Q, Liu Y, Xiao Y, et al. Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome. Mol Med Rep. 2017;16:8164-8170. [Crossref]
  • 27. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13. [Crossref]
  • 28. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981-1030. [Crossref]
  • 29. Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocrine Soc. 2019;3:1545-1573. [Crossref]
  • 30. Varanka Z, Rojik I. VarankaI, Nemcsók J, Ábrahám M. Biochemical and morphological changes in crap liver following ex- posure to copper sulfate and tannic acid. Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology 2001;128:467-478. [Crossref]
  • 31. Jahan S,Abid A, Khalid S,Afsar T, Qurat-Ul-Ain, Shaheen G, et al.Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study. J Ovarian Res. 2018;11:26. [Crossref]
  • 32. Osuka S, Nakanishi N, Murase T, Nakamura T, Goto M, Iwase A, et al. Animal models of polycystic ovary syndrome: A review of hormone-induced rodent models focused on hypothalamus-pituitary-ovary axis and neuropeptides. Reprod Med Biol. 2018;18:151-160. [Crossref]
  • 33. Aydos A, Oztemur Y, Dedeoglu BG. Polycystic ovary syndrome and molecular approaches. Turk Hij Den Biyol Derg. 2016;73:81-88.[Crossref]
  • 34. Sun L, Ji C, Jin L, Bi Y, Feng W, Li P, et al. Effects of Exenatide on metabolic changes, sexual hormones, inflammatory cytokines, adipokines, and weight change in a DHEA-treated rat model. Reprod Sci. 2016;23:1242- 1249. [Crossref]
  • 35. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20:193-205. [Crossref]
  • 36. Hoseinpour MJ, Ghanbari A, Azad N, Zare A, Abdi S, Sajadi E, et al. Ulmus minor bark hydro-alcoholic extract ameliorates histological parameters and testosterone level in an experimental model of PCOS rats. Endocr Regul. 2019;53:146-153. [Crossref]
  • 37. Joseph-Horne R, Mason H, Batty S, White D, Hillier S, Urquhart M, et al. Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum Reprod. 2002;17:1459-1463. [Crossref]
  • 38. Miller BH, Takahashi JS. Central circadian control of female reproductive function. Front Endocrinol (Lausanne). 2014;4:195. [Crossref]
  • 39. Bennett MR, Littlewood TD, Schwartz SM, Weissberg PL. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ Res. 1997;81:591-599. [Crossref]
  • 40. Homburg R,Amsterdam A.Polycystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles? J Endocrinol Invest. 1998;21:552-557. [Crossref]
  • 41. Cui X, Jing X, Wu X, Bi X, Liu J, Long Z, et al. Abnormal expression levels of BMP15/Smad1 are associated with granulosa cell apoptosis in patients with polycystic ovary syndrome. Mol Med Rep. 2017;16:8231-8236. [Crossref]
APA GÜMÜŞKAYA F, SAPMAZ T, CANBAZ H, TOPKARAOGLU S, SEVGIN K, Tekayev M, aktaş s, PENÇE M, irkorucu O (2022). Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. , 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
Chicago GÜMÜŞKAYA FATMA,SAPMAZ Tansel,CANBAZ HALIME TUBA,TOPKARAOGLU SUDE,SEVGIN KUBRA,Tekayev Muhammetnur,aktaş selman,PENÇE MAHMUD ESAD,irkorucu Oktay Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. (2022): 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
MLA GÜMÜŞKAYA FATMA,SAPMAZ Tansel,CANBAZ HALIME TUBA,TOPKARAOGLU SUDE,SEVGIN KUBRA,Tekayev Muhammetnur,aktaş selman,PENÇE MAHMUD ESAD,irkorucu Oktay Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. , 2022, ss.99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
AMA GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. . 2022; 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
Vancouver GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. . 2022; 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
IEEE GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O "Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study." , ss.99 - 107, 2022. 10.4274/hamidiyemedj.galenos.2022.07078
ISNAD GÜMÜŞKAYA, FATMA vd. "Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study". (2022), 99-107. https://doi.org/10.4274/hamidiyemedj.galenos.2022.07078
APA GÜMÜŞKAYA F, SAPMAZ T, CANBAZ H, TOPKARAOGLU S, SEVGIN K, Tekayev M, aktaş s, PENÇE M, irkorucu O (2022). Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. Hamidiye Medical Journal , 3(2), 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
Chicago GÜMÜŞKAYA FATMA,SAPMAZ Tansel,CANBAZ HALIME TUBA,TOPKARAOGLU SUDE,SEVGIN KUBRA,Tekayev Muhammetnur,aktaş selman,PENÇE MAHMUD ESAD,irkorucu Oktay Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. Hamidiye Medical Journal 3, no.2 (2022): 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
MLA GÜMÜŞKAYA FATMA,SAPMAZ Tansel,CANBAZ HALIME TUBA,TOPKARAOGLU SUDE,SEVGIN KUBRA,Tekayev Muhammetnur,aktaş selman,PENÇE MAHMUD ESAD,irkorucu Oktay Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. Hamidiye Medical Journal , vol.3, no.2, 2022, ss.99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
AMA GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. Hamidiye Medical Journal . 2022; 3(2): 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
Vancouver GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study. Hamidiye Medical Journal . 2022; 3(2): 99 - 107. 10.4274/hamidiyemedj.galenos.2022.07078
IEEE GÜMÜŞKAYA F,SAPMAZ T,CANBAZ H,TOPKARAOGLU S,SEVGIN K,Tekayev M,aktaş s,PENÇE M,irkorucu O "Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study." Hamidiye Medical Journal , 3, ss.99 - 107, 2022. 10.4274/hamidiyemedj.galenos.2022.07078
ISNAD GÜMÜŞKAYA, FATMA vd. "Therapeutic Potential of Tannic Acid in the Management of Polycystic Ovarian Syndrome (PCOS) in Letrozole Induced Rat Model: A Histological and a Biochemical Study". Hamidiye Medical Journal 3/2 (2022), 99-107. https://doi.org/10.4274/hamidiyemedj.galenos.2022.07078